Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …

Objectives: The HIV-infected population is known to be oxidatively stressed and deficient in
antioxidant micronutrients. Since in vitro replication of HIV is increased with oxidative stress, …

Background Between May and November, 2022, global outbreaks of human monkeypox
virus infection have been reported in more than 78 000 people worldwide, predominantly in …

MATERIALS AND METHODS Patient population. The Hospital for Sick Children is a 535-bed
university-affiliated pediatric hospital in Toronto, Ontario, Canada, providing primary, …

Methods: Gemini was a 48-week, multicenter, open-label, noninferiority trial in treatment-naive
HIV-1-infected adults randomized to either saquinavir/ritonavir (SQV/r) 1000 mg/100 mg …

Background Before April 2022, monkeypox virus infection in humans was seldom reported
outside African regions where it is endemic. Currently, cases are occurring worldwide. …

ContextSevere acute respiratory syndrome (SARS) is an emerging infectious disease that
first manifested in humans in China in November 2002 and has subsequently spread …

Context The availability of new antiretroviral drugs and formulations, including drugs in new
classes, and recent data on treatment choices for antiretroviral-naive and -experienced …

Background The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized,
open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) …

Background Lopinavir is a newly developed inhibitor of human immunodeficiency virus (HIV)
protease that, when formulated with ritonavir, yields mean trough plasma lopinavir …